Oncotest GmbH and Debiopharm Group Announce a Successful Partnership in the Identification of Biomarker Candidates
LAUSANNE, Switzerland, April 24, 2013 /PRNewswire/ --
XBiotech Enrolls First Patient in Phase III Pivotal Trial of Xilonix™
Trial Results to be Submitted For U.S.
Gilead Sciences Supports HarborPath's HIV/AIDS Medication Assistance Pilot Program
− HarborPath Partners Now Include Gilead Sciences, Merck and ViiV Healthcare -
COLUMBIA, S.C., April 24, 20
Malaria No More Announces Innovative Partners For Its 'Power Of One' Malaria Campaign
Novartis, Alere, Time Warner, Twitter, and more sign on to help close malaria testing and treatment gaps in Africa
NEW YORK,
Boehringer Ingelheim consistently continues growth phase in financial year 2012
Boehringer Ingelheim consistently continues growth phase in financial year 2012 • Net sales rose by 11.5 percent to around €14.7 billion • High future-oriented investment again in...
Lilly Reports First-Quarter 2013 Results
Lilly Reports First-Quarter 2013 Results INDIANAPOLIS, April 24, 2013-- Worldwide revenue was flat as growth in key products offset lower Zyprexa revenue following patent expirations. Cymbalta...
Results announcement for the first quarter 2013
Results announcement for the first quarter 2013
Wednesday 24 April 2013, London UK GSK delivers Q1 2013 core EPS of 26.9p and dividend of 18p Core EPS of 26.9p and dividend of 18p Group...
Novartis discloses compensation for new Chairman and Chairman ad-interim
Novartis discloses compensation for new Chairman and Chairman ad-interim April 24, 2013
Dr. Joerg Reinhardt to receive total annual compensation of CHF 3.8 million through combination...
Novartis delivered solid performance in the first quarter, with eight key regulatory approvals and all divisions contributing to growth
Novartis delivered solid performance in the first quarter, with eight key regulatory approvals and all divisions contributing to growth April 24, 2013
Group net sales of USD 14.0 billion grew...
Manhattan U.S. Attorney Files Healthcare Fraud Lawsuit Against Novartis Pharmaceuticals Corp. For Orchestrating A Multi-Million Dollar Prescription Drug Kickback Scheme
Manhattan U.S. Attorney Files Healthcare Fraud Lawsuit Against Novartis Pharmaceuticals Corp. For Orchestrating A Multi-Million Dollar Prescription Drug Kickback Scheme Tuesday, April 23, 2013 Suit...
Halozyme Initiates Randomized Phase 2 Trial of PEGPH20 in Pancreatic Cancer
Randomized trial to test PEGPH20 in conjunction with most advanced chemotherapy backbone
SAN DIEGO, April 2
Johnson & Johnson to Host Pharmaceuticals Business Review
NEW BRUNSWICK, N.J., April 23, 2013 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will host a review
More Than Half of Nasal Allergy Sufferers Experience Sleep Issues, Yet Many Fail to Adequately Prepare in Advance of Peak Allergy Seasons
New Survey Reveals the Impact of Nasal Allergies on Sleep, Relationships and Productivity
LANDOVER, Md., Ap
Former Pro Football Coach Bill Cowher Tells Men "No Excuses" When It Comes To Getting Screened For Melanoma
New survey shows one in six men don't want to get a skin cancer screening because they are afraid of what they will hear
NEW YORK,
Amgen's First Quarter 2013 Revenues Increased 5 Percent To $4.2 Billion And Adjusted Earnings Per Share (EPS) Increased 22 Percent To $1.96
First Quarter 2013 GAAP EPS Were $1.88
THOUSAND OAKS, Calif., April 23, 2013 /PRNewswire/ -- Amgen (
Forest Laboratories, Inc. Reports Fiscal Year Fourth Quarter 2013 Earnings Per Share of $0.17 Including $0.08 Per Share of Acquisition Amortization
Forest Laboratories, Inc. Reports Fiscal Year Fourth Quarter 2013 Earnings Per Share of $0.17 Including $0.08 Per Share of Acquisition Amortization
Company Provides Fiscal Year 2014 Non-GAAP...
Mayo Clinic and Acorda Therapeutics Announce Initiation of Phase 1 Trial of Remyelinating Antibody in People with Multiple Sclerosis
Mayo Clinic and Acorda Therapeutics Announce Initiation of Phase 1 Trial of Remyelinating Antibody in People with Multiple Sclerosis
Before the Bell Scans of Agilent Technologies, Thermo Fisher Scientific, PerkinElmer, Laboratory Corp. of America, and Alere
LONDON, April 22, 2013 /PRNewswire/ --
Lundbeck introduces Selincro® as the first and only medicine for the reduction of alcohol consumption in alcohol dependent patients
April 22, 2013 Lundbeck introduces Selincro® as the first and only medicine for the reduction of alcohol consumption in alcohol dependent patients Lundbeck launches Selincro® in Norway,...
